Flu Vaccine Response Boosted by Coupling Antigens from Multiple Subtypes
Can Your Genes Predict Your Flu Shot’s Effectiveness? New Research Suggests They Might
Stanford, CA – Every year, millions of Americans roll up their sleeves for the seasonal flu shot, hoping to ward off the potentially deadly influenza virus. but why do some people seem to benefit more from the vaccine than others? A groundbreaking study from Stanford Medicine researchers suggests that our genes may play a bigger role than previously thought in determining how well we respond to the flu vaccine.
The study, published in the prestigious journal Science, also presents a promising new vaccine platform that could offer broader protection against diverse influenza subtypes, potentially even those with pandemic potential.
“The flu virus is a serious public health threat, causing hundreds of thousands of deaths worldwide each year,” said Mark Davis, PhD, professor of microbiology and immunology at Stanford and lead author of the study. ”While the seasonal flu vaccine is an important tool,its effectiveness can vary considerably from person to person.”
The current flu vaccine contains a mix of hemagglutinin (HA) molecules, the ”hooks” the virus uses to latch onto our cells. Ideally, the vaccine primes our immune system to recognize and fight off various circulating flu strains. However, many individuals develop a stronger immune response to one strain in the vaccine, leaving them vulnerable to others.
This phenomenon, known as “original antigenic sin,” suggests that our first encounter with a flu virus can shape our immune response for life.
“Our research indicates that host genetics might potentially be a more critically important driver of thes variable responses than previously thought,” explained Davis. “This means that our genes could be influencing how effectively our bodies respond to the flu vaccine.”
The Stanford team’s innovative approach involves coupling antigens from multiple influenza subtypes together. This novel vaccine platform,tested in animal models and human tonsil-derived organoids,showed promising results in broadening antibody and T cell responses,offering potentially wider protection against diverse flu strains.
“This new vaccine platform could be a game-changer in the fight against influenza,” said Davis. “It has the potential to provide more robust and long-lasting protection against a wider range of flu viruses, including those with pandemic potential.”
While further research is needed, this study offers a glimmer of hope for a more effective and universal flu vaccine, one that could finally break the cycle of seasonal vulnerability and protect us from this persistent threat.
Scientists Develop Universal Flu Vaccine to Combat Subtype Bias and Pandemic Threats
New research offers hope for a more effective flu vaccine that could protect against a wider range of influenza strains, including potentially pandemic-causing avian flu.
Scientists at the Scripps Research Institute have made a significant breakthrough in the fight against influenza. Their research, published in a leading scientific journal, reveals a novel vaccine design that could overcome the limitations of current flu shots and provide broader protection against a wider range of influenza subtypes.
The team, led by Dr. Richard Davis, focused on a phenomenon known as ”subtype bias,” where individuals exhibit uneven immune responses to different influenza subtypes. This bias, they discovered, is primarily driven by an individual’s genetics, specifically variations in the major histocompatibility complex (MHC) class-II genes, which play a crucial role in immune recognition.
“We found that although prior exposure is a factor, host genetics are a stronger driver of subtype bias to influenza viral strains,” the scientists wrote in their paper.
This genetic predisposition makes it challenging to develop a universal flu vaccine that effectively targets all subtypes. To address this, the researchers designed a unique vaccine construct featuring four hemagglutinin (HA) varieties – the key surface protein of the influenza virus – chemically linked together on a molecular scaffold.This innovative approach forces B cells, the immune cells responsible for antibody production, to internalize the entire matrix containing all four HA subtypes. This, in turn, leads to a more robust immune response, as helper T cells, which are essential for activating B cells, are more likely to encounter their target antigen.
“We found that covalent coupling of heterologous hemagglutinin (HA) from different viral strains could largely eliminate subtype bias in an animal model and in a human tonsil organoid system,” the scientists wrote.The team tested their vaccine in human tonsil organoids,miniature lymph nodes grown in a lab dish,and observed a significant increase in antibody production against all four influenza strains.
Furthermore, they demonstrated the potential of this vaccine to combat avian influenza, a highly pathogenic strain with pandemic potential. By adding the avian flu HA to the four-antigen construct, they were able to substantially boost the antibody response against this threat.
This groundbreaking research offers a promising avenue for developing a truly universal flu vaccine, capable of providing broader and more durable protection against a wider range of influenza subtypes, including those with pandemic potential.
Scientists Develop Promising New Strategy to Combat Flu Pandemics
Researchers at the University of Washington have made a breakthrough in the fight against influenza, potentially paving the way for more effective vaccines that could protect against a wider range of flu strains, including those responsible for bird flu.
For decades, scientists have struggled with the phenomenon known as “subtype bias,” where flu vaccines are less effective against certain strains, particularly those that are significantly different from the strains circulating in the human population. This bias has been a major obstacle in developing truly universal flu vaccines.
The new research,published in the journal Science,offers a novel solution. The team, led by Dr.michael Gale Jr., discovered that by combining different flu proteins – specifically, hemagglutinin (HA) from both H5N1 (bird flu) and seasonal flu strains – they could significantly enhance the immune response.
“Whereas tonsil organoids stimulated with H5N1 HA alone induced very weak antibody responses, a coupled heterologous antigen with an optimal ratio of H5N1 HA and seasonal HA that maximized cross-subtype T cell help induced higher antibody responses,” explained Dr. Gale.
This approach, known as “coupling heterologous antigens,” essentially boosts the body’s T cell response, which plays a crucial role in recognizing and fighting off infections.
“Overcoming subtype bias this way can lead to a much more effective influenza vaccine,extending even to strains responsible for bird flu,” Dr.gale added. “the bird flu could very likely generate our next viral pandemic.”
The researchers beleive this strategy could be applied to other pathogens as well, potentially leading to more effective vaccines against a range of infectious diseases.
“For many decades, the OAS hypothesis has influenced the clarification of subtype bias,” the team noted in their paper. Though, they pointed out that this hypothesis doesn’t offer any practical solutions for improving vaccine efficacy. ”by contrast, our study shows that coupling heterologous antigens may broaden T cell help and improve vaccine efficacy. This strategy to augment T cell help is readily applicable to vaccines for other pathogens for which multistrain coverage is needed.”